Loading viewer...
earnings
Format: PDF earnings
J.P. Morgan equity research alert on OPKO's phase 3 study of hGH-CTP in adults with growth hormone deficiency, which failed to meet its primary endpoint on trunk fat mass reduction. Despite the disappointing adult results, the company initiated its pediatric phase 3 study, which represents approximately 75% of the total market opportunity.
investor_presentation
27 Pages
OPKO Health Investor Presentation — September 2017
investor_presentationinvestor_presentation
23 Pages
earnings
12 Pages
American Electric Power Company
The Hartford 2023 Financial Results and Q4 Earnings
earningsearnings
24 Pages
The Hartford Financial Services Group, Inc.
Bajaj Finance Q4 FY22 Investor Presentation 2022
earningsearnings
66 Pages
Bajaj Finance Limited